Skip to main content

Archived Comments for: Updates in Gastrointestinal Oncology – insights from the 2008 44th annual meeting of the American Society of Clinical Oncology

Back to article

  1. Erratum

    Chung-Tsen Hsueh, Loma Linda University

    14 December 2009

    The corresponding author want to point out there is misplacement of cited referrences 15 and 16 in the final publication. The correct placement is as followed in page 3 of pdf publication.

    The European Medicines Agency has recognized these findings, and restricts the use of anti-EGFR antibody in CRC patients only with wild-type KRAS tumors [15].

    National Cancer Institute (NCI) has suspended all ongoing U.S. cooperative group studies involving anti-EGFR antibody in CRC since June 2008 [16]. NCI has amended N0147 study, which is an adjuvant trial comparing cetuximab plus FOLFOX vs. FOLFOX in patients with stage III colon cancer after surgery. After amendment, only patients with wild-type KRAS tumors will be randomized for protocol treatment [17].

    Competing interests

    I have no competing interest.